Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

Real‐world first‐line systemic therapy patterns in metastatic castration‐resistant prostate cancer

Abstract Introduction Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have received docetaxel first, unless unsuitable...

Full description

Bibliographic Details
Main Authors: Angelyn Anton, Sruti Pillai, Marie Christine Semira, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M. Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Olivia Baenziger, Peter Gibbs, Ben Tran
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:BJUI Compass
Subjects:
abiraterone
docetaxel
enzalutamide
metastatic castration‐resistant prostate cancer
real‐world data
systemic therapy
Online Access:https://doi.org/10.1002/bco2.129

Internet

https://doi.org/10.1002/bco2.129

Similar Items